Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-11417 in Adult Patients With Mature B-cell Malignancies
NCT04883957Phase 1Completed
- Sponsor
- BeiGene
- Start
- Jul 2021
- Primary completion
- Sep 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of sonrotoclax in mature B-cell neoplasms (MBN), non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) and 4 more (3 cohorts), sponsored by BeiGene. Primary endpoints: Maximum Tolerated Dose at 3 years, Recommended Phase 2 Dose at 3 years and 2 more. Started Jul 2021; status: completed.
02
Drugs
sonrotoclax
03
Conditions
mature B-cell neoplasms (MBN)non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04883957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04883957.